share_log

和黃醫藥：自願性公告－和黃醫藥將於2024年歐洲血液協會 (EHA) 年會公佈索樂匹尼布(sovleplenib) ESLIM-01 III期研究以及血液惡性腫瘤項目數據

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

Hong Kong Stock Exchange ·  May 17 08:01
Summary by Futu AI
和黃醫藥（HUTCHMED）將於2024年6月13日至16日在西班牙馬德里舉行的歐洲血液協會年會上，公佈索樂匹尼布ESLIM-01 III期研究的頂線及亞組結果。該研究是在中國進行的III期臨床試驗，針對原發免疫性血小板減少症患者，結果顯示索樂匹尼布具有臨床意義的快速且持久的血小板計數應答。此外，公司還將公佈其他血液惡性腫瘤療法的最新臨床數據。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已在中國和美國市場上市三種藥物。
和黃醫藥（HUTCHMED）將於2024年6月13日至16日在西班牙馬德里舉行的歐洲血液協會年會上，公佈索樂匹尼布ESLIM-01 III期研究的頂線及亞組結果。該研究是在中國進行的III期臨床試驗，針對原發免疫性血小板減少症患者，結果顯示索樂匹尼布具有臨床意義的快速且持久的血小板計數應答。此外，公司還將公佈其他血液惡性腫瘤療法的最新臨床數據。和黃醫藥是一家專注於癌症和免疫性疾病治療的生物醫藥公司，已在中國和美國市場上市三種藥物。
HUTCHMED WILL ANNOUNCE THE TOP LINE AND SUBGROUP RESULTS OF THE SOLOPINIB ESLIM-01 PHASE III STUDY AT THE EUROPEAN BLOOD ASSOCIATION ANNUAL MEETING IN MADRID, SPAIN, FROM 13 TO 16 JUNE 2024. The study, a Phase III clinical trial in China in patients with primary immunodeficiency, showed that solepinib has a clinically meaningful rapid and sustained platelet count response. In addition, the company will publish the latest clinical data for other blood malignant tumor therapies. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases, which has marketed three drugs in China and the United States.
HUTCHMED WILL ANNOUNCE THE TOP LINE AND SUBGROUP RESULTS OF THE SOLOPINIB ESLIM-01 PHASE III STUDY AT THE EUROPEAN BLOOD ASSOCIATION ANNUAL MEETING IN MADRID, SPAIN, FROM 13 TO 16 JUNE 2024. The study, a Phase III clinical trial in China in patients with primary immunodeficiency, showed that solepinib has a clinically meaningful rapid and sustained platelet count response. In addition, the company will publish the latest clinical data for other blood malignant tumor therapies. Wah Wong Pharmaceuticals is a biopharmaceutical company focused on the treatment of cancer and immune diseases, which has marketed three drugs in China and the United States.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.